GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™) in combination with azacitidine (the current standard of care) versus placebo in combination with azacitidine in intermediate-1, intermediate-2 or high risk patients with myelodysplastic syndromes (MDS). The global study will assess the proportion of patients who are platelet transfusion free during the first four cycles of treatment.
GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes | 2014 | Press releases | Media | GlaxoSmithKline
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.